The EMEA's Committee for Human Medicinal Products (CHMP) is reviewing issues related to the treatment with and supply of heparin products. The review was initiated following the detection of a contaminant in batches of medicinal products containing or derived from heparin in the USA and a few EU countries.
The procedure was initiated at the request of Germany under Article 5(3) of Regulation (EC) No 726/2004.
You can read our previous heparin announcements in the factbox to the right.
For further information, please contact Chief Medical Officer Steffen Thirstrup, tel. +45 4488 9187.
Danish Medicines Agency, 25 April 2008